SELLAS Life Sciences Group, Inc.

SLS · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $0.9B · 13 employees
437
SEC Filings
$10.49
Close 2026-10-19
13
Employees

Business Summary

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product, galinpepimut-S (GPS), is a peptide immunotherapy targeting the WT1 antigen licensed from Memorial Sloan Kettering Cancer Center, currently in a Phase 3 trial (REGAL study) for AML. Its second candidate, SLS009 (tambiciclib), is a selective CDK9 inhibitor licensed from GenFleet Therapeutics, in Phase 2 trials for AML and lymphomas.

Latest Stock Quote

SLS 2026-10-19 $10.49 O:$10.1 H:$10.85 L:$10.04 Vol:5.6M VWAP:$10.5141
origin leaf: null

Next Earnings

expected 2027-02-11

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001390478-26-000003EDGAR101K words
2025-03-202024-12-310001390478-25-000003EDGAR103K words
2024-03-282023-12-310001390478-24-000004EDGAR104K words
2023-03-162022-12-310001390478-23-000005EDGAR100K words
2022-03-312021-12-310001390478-22-000006EDGAR97K words
2021-03-232020-12-310001390478-21-000007EDGAR99K words
2020-03-132019-12-310001390478-20-000007EDGAR96K words
2019-03-222018-12-310001390478-19-000017EDGAR92K words
2018-04-132017-12-310001193125-18-117053EDGAR110K words
2017-03-152016-12-310001390478-17-000020EDGAR59K words

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-11-122026-09-300001390478-26-000020EDGAR15K words
2026-08-112026-06-300001390478-26-000012EDGAR14K words
2025-11-122025-09-300001390478-25-000020EDGAR16K words
2025-08-122025-06-300001390478-25-000016EDGAR15K words
2025-05-132025-03-310001390478-25-000008EDGAR14K words
2024-11-132024-09-300001390478-24-000021EDGAR16K words
2024-08-132024-06-300001390478-24-000015EDGAR16K words
2024-05-142024-03-310001390478-24-000010EDGAR14K words
2023-11-092023-09-300001390478-23-000024EDGAR18K words
2023-08-102023-06-300001390478-23-000019EDGAR18K words
2023-05-112023-03-310001390478-23-000012EDGAR16K words
2022-11-142022-09-300001390478-22-000028EDGAR19K words

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-11-120001390478-26-000021EDGAR2K words
2026-08-110001390478-26-000013EDGAR2K words
2026-07-270001104659-26-087110EDGAR1K words
2026-03-190001390478-26-000004EDGAR2K words
2026-03-110001104659-26-026384EDGAR1K words
2026-01-080001104659-26-001957EDGAR1K words
2025-11-120001390478-25-000021EDGAR2K words
2025-10-270001104659-25-102345EDGAR1K words
2025-10-030001104659-25-096643EDGAR1K words
2025-09-110001104659-25-089272EDGAR1K words

437 total filings indexed. 405 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACIU — AC Immune SA ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA

Tags

acute-myeloid-leukemia-(aml) hematologic-malignancies solid-tumor-oncology pediatric-oncology peripheral-t-cell-lymphoma-(ptcl) multiple-myeloma malignant-pleural-mesothelioma

Company Identity

CIK0001390478
TickerSLS
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE
Websitehttps://www.sellaslifesciences.com
Listed2008-03-12

Get More Data

This is a static snapshot. For live, structured JSON with cryptographic provenance chain:

MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp

JSON Profile Stock Quote Origin Record
Origin Provenance
page leaf: 6f2d51b70aa8cdf3892174f6b871e29ee7e3daf9b0cf934031edf2d3cc0fa13c
parent: 56a75b593638d4e3f7c38a44db9b9d3a054c744e6aee5c87fdfaef01359eaa84
content hash: b3d114f310c565498258246b105cbc07cc22683cc51124ce8906ddbdcf18f680
signed: 2026-11-16T19:04:48.508Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf

Try it — paste this into your AI:

Look up SLS using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?

Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.

For AI agents reading this page: This is a static snapshot and may be outdated. For live data on SLS, use the Origin MCP server or REST API.
MCP install: claude mcp add origin --transport http https://origin.rootz.global/mcp
API: GET https://origin.rootz.global/api/company/SLS (~200 tokens, structured JSON with cryptographic provenance)
Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill
Discovery: /.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.